Potential short squeeze plays gained steam in 2021 and has continued through 2022 with new traders looking for the next huge move.
Here’s a look at the top five short squeeze candidates based on the Fintel short squeeze leaderboard.
Greenwich LifeSciences: Clinical stage biopharmaceutical company Greenwich LifeSciences GLSI moved back up to the top of the Fintel short squeeze leaderboard after ranking third last week. Data showed 28.5% of the float short, up from last week’s 27.5% reported. The cost to borrow on shares is 11.1%, down slightly from last week’s 11.6% reported.
Aerovate Therapeutics: Clinical stage biopharmaceutical company Aerovate Therapeutics AVTE jumped 18 places on the leaderboard to rank second for the week. Data showed 31.5% of the float short, the highest rate of the top five short-squeeze candidates. The cost to borrow on shares is 6.8%.
HeartBeam Inc: Heart attack detection technology company HeartBeam Inc BEAT made the biggest jump on the leaderboard, moving up 968 positions to third place. Data shows 11.7% of the float short. While the short percentage was the lowest of the top five short squeeze candidates, the cost to borrow will likely jump out to investors. Fintel reported a cost to borrow of 397.8%, one of the highest for the week.
Minerva Neurosciences: Clinical stage biopharmaceutical company Minerva Neurosciences Inc NERV ranked fourth on the short squeeze leaderboard, in line with last week’s ranking. Data showed 12.2% of the float short, down from last week’s reported 23.2%. The cost to borrow on shares is 79.7%. The company previously topped the short squeeze leaderboard in September.
Virgin Orbit Holdings: Satellite launch and space technology company Virgin Orbit Holdings Inc VORB jumped 38 places to rank fifth on the short squeeze leaderboard. Data showed 18.1% of the float short and a cost to borrow of 95.8%. The company, which went public via SPAC merger has shares currently near a 52-week low of $2.50 versus a 52-week high of $11.28.
Photo: gguy via Shutterstock
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.